EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study

Youyou Shao, Jingying Zhang, Zhi Feng, Wei Wu, Xiaotian Zhao, Minyi Zhu, Yao Xiao, Jiaohui Pang, Junfei Zhu, Hao Qu, Minchi Yuan, Guojie Xia und 2 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16250 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Science, 2024. Verfasst von Youyou Shao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Provincial Medicine and Health Research Foundation, The Natural Science Foundation of Zhejiang Province, Traditional Chinese Medical Science and Technology Plan of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atypical L858R or other L858X mutations in the epidermal growth factor receptor (EGFR) gene, beyond the classical EGFR L858R mutation caused by c.2573 T > G, have been identified in non‐small cell lung cancer (NSCLC), yet their genomic features and survival benefits with EGFR tyrosine kinase inhibitor (TKI) treatment have not been fully explored. We retrospectively enrolled 489 NSCLC patients with baseline tumor tissue/plasma samples carrying uncommon EGFR L858R ( N = 124), EGFR L858Q/M ( N = 17), or classical EGFR L858R mutations ( N = 348). The comparison of molecular features was performed using treatment‐naïve tumor tissues. Survival benefits and resistance mechanisms of first‐line EGFR TKI treatment were studied in an advanced disease subcohort. NSCLCs harboring uncommon EGFR L858R had lower TP53 mutation prevalence ( p = 0.04) and chromosome instability scores ( p = 0.02) than those with classical EGFR L858R . Concomitant EGFR L861Q mutations were enriched in NSCLCs with EGFR L858Q/M ( p < 0.01), with cooccurrence in those carrying EGFR L858M . Patients with uncommon EGFR L858R experienced improved progression‐free survival (PFS) compared to those with classical EGFR L858R (median: 13.0 vs. 10.0 months, hazard ratio [HR]: 0.57, 95% confidence interval [CI]: 0.41–0.80). The association remained significant when adjusting for sex, age, histological subtype, TKI category, and anti‐vascular therapy (HR: 0.55, 95% CI: 0.39–0.77). Furthermore, EGFR L858Q/M patients showed enhanced first‐line PFS (vs. classical EGFR L858R , HR: 0.26, 95% CI: 0.10–0.67), potentially benefiting more from afatinib. Additionally, NSCLCs with uncommon EGFR L858R and classical EGFR L858R had similar resistance profiles to EGFR TKIs. In conclusion, NSCLCs carrying atypical EGFR L858 aberrations, which had fewer TP53 mutations and higher chromosome stability, exhibited improved PFS under first‐line EGFR TKIs than those with the classical EGFR L858R .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDrug Resistance, NeoplasmRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

EGFR L858REGFREGFR tyrosine kinase inhibitorfirst‐line treatmentnon‐small cell lung cancer

Substanzen

EGFR protein, humanErbB ReceptorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Thyroid Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
  • Department of Respiratory and Critical Care Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.

ORCID-Profile: Hengyuan Li

Förderung

  • Zhejiang Provincial Medicine and Health Research Foundation
  • The Natural Science Foundation of Zhejiang Province
  • Traditional Chinese Medical Science and Technology Plan of Zhejiang Province
  • Zhejiang Provincial Traditional Chinese Medicine Science Research Foundation
  • Medical and Health Science and Technology Plan of Department of Health of Zhejiang Province
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Shao, Y., Zhang, J., Feng, Z., Wu, W., Zhao, X., Zhu, M., Xiao, Y., Pang, J., Zhu, J., Qu, H., Yuan, M., Xia, G., Liu, M., & Li, H. (2024). Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study. Cancer Science. https://doi.org/10.1111/cas.16250

Vancouver

Shao Y, Zhang J, Feng Z, Wu W, Zhao X, Zhu M, et al. Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study. Cancer Science. 2024. doi:10.1111/cas.16250

BibTeX
@article{Shao2024,
  author = {Shao, Youyou and Zhang, Jingying and Feng, Zhi and Wu, Wei and Zhao, Xiaotian and Zhu, Minyi and Xiao, Yao and Pang, Jiaohui and Zhu, Junfei and Qu, Hao and Yuan, Minchi and Xia, Guojie and Liu, Meng and Li, Hengyuan},
  title = {Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16250}
}
Kostenlos starten →